|
|
Article: PhotoPoint PDT Targets Both Tumor Cells and Blood Vessels in Preclinical Breast Cancer Study; Results Published in August 1st Issue of Journal ``Cancer Research''.
- Article from:
- Business Wire
- Article date:
- August 6, 2002
CopyrightCOPYRIGHT 2002 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Business Editors & Health/Medical Writers
SANTA BARBARA, Calif.--(BW HealthWire)--Aug. 6, 2002
Miravant Medical Technologies (OTCBB:MRVT), a pharmaceutical development company specializing in PhotoPoint(TM) photodynamic therapy (PDT), announced today that the proprietary PhotoPoint drug MV6401 achieved selective shutdown of tumor blood vessels and long-term tumor growth delay in a unique PDT study in an orthotopic breast tumor model. The research was undertaken at one of the world's premier tumor research laboratories, the Edwin L. Steele Laboratory for Tumor Biology, Massachusetts General Hospital, Boston, under the direction of Professor Rakesh Jain, ...